Fintel on MSN23h
Leerink Partners Initiates Coverage of Zura Bio (ZURA) with Outperform Recommendation
Fintel reports that on November 4, 2024, Leerink Partners initiated coverage of Zura Bio (NasdaqCM:ZURA) with a Outperform ...
Molecular Partners’ Promising Pipeline and Financial Stability Justify Buy Rating
In a report released on November 1, Jonathan Chang from Leerink Partners reiterated a Buy rating on Molecular Partners (MOLN – Research ...
bovnews3h
Stock Shock: The Unpredictable Rise and Fall of NVST—What’s Driving the Drama?
On Monday, Envista Holdings Corp (NVST) stock saw a modest uptick, ending the day at $21.28 which represents a slight increase of $0.34 or 1.62% from the prior close of $20.94. The stock opened at $21 ...
Merus’s Promising Pipeline and Financial Strength Support Buy Rating
Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...
bovnews4h
What’s Behind the 2.79% Gain in Henry Schein, Inc. (HSIC) Stock? Find Out Now!
On Monday, Henry Schein, Inc. (HSIC) stock saw a modest uptick, ending the day at $72.33 which represents a slight increase of $1.96 or 2.79% from the prior close of $70.37. The stock opened at $71 ...
FiercePharma3h
Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs
To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...
BioSpace3h
FDA Delays Decision on Merus Bispecific Antibody to Review CMC Information
Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...
Reuters5h
Henry Schein beats quarterly profit estimates on lower costs
The results "showed strong cost discipline in the face of a tough operating environment," Leerink Partners analyst Michael Cherny said in a note. The company raised the lower end of its adjusted ...
ETF Daily News18h
R1 RCM (NASDAQ:RCM) Shares Cross Above 200 Day Moving Average – What’s Next?
Leerink Partners lowered R1 RCM from an “outperform” rating to a “market perform” rating and cut their target price for the company from $17.00 to $14.30 in a research report on Thursday, August 1st.
Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, ...
Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now?
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Q3 2024 Abcellera Biologics Inc Earnings Call
Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion of today's interactive broadcast. (Operator Instructions).